• Q4 2023 Revenue: Increased by 21.0% year over year to $106.5 million.

• Full Year 2023 Revenue: Grew by 20.8% to $399.2 million, with U.S. and International revenues up by 20.3% and 23.5%, respectively.

• Net Loss Improvement: Full Year 2023 net loss improved by $16.0 million year over year.

• Adjusted EBITDA: Positive $19.4 million for Full Year 2023, a $21.6 million improvement from the previous year.

• 2024 Financial Guidance: Projected revenue of approximately $459 million to $466 million, with adjusted EBITDA expected to be $26 million to $29 million.

• Warning! GuruFocus has detected 2 Warning Signs with ATRC.

On February 15, 2024, AtriCure Inc (NASDAQ:ATRC) released its 8-K filing, detailing its financial results for the fourth quarter and full year of 2023. The company, a leader in surgical treatments for atrial fibrillation and related conditions, reported a significant increase in worldwide revenue, marking a 21.0% rise in Q4 2023 compared to the same period in the previous year. Full-year revenue also saw a substantial increase, climbing to $399.2 million, a 20.8% year-over-year growth.

AtriCure's U.S. revenue for the full year reached $333.5 million, while international revenue grew to $65.7 million, reflecting robust growth across all franchises and major geographic regions. The company's net loss for the full year showed considerable improvement, decreasing by $16.0 million from the previous year. Additionally, AtriCure achieved a positive adjusted EBITDA of $19.4 million for the full year, a significant improvement from the prior year.

Financial Highlights and Operational Performance

The fourth quarter's gross profit stood at $79.8 million with a gross margin of 74.9%, showing an improvement of 94 basis points over the same quarter in the previous year. Despite an increase in loss from operations due to investments in clinical trials and product development, the company's adjusted EBITDA remained positive at $4.8 million for Q4 2023. The basic and diluted net loss per share was $0.21 for the same period.

AtriCure's President and CEO, Michael Carrel, commented on the results, emphasizing the company's progress towards sustained profitability and its focus on innovation and clinical science. He stated,

Our 2023 results showcase the broad-based expansion of our many growth drivers, balanced by disciplined investments as we make progress towards sustained profitability."

For the full year 2023, AtriCure's gross profit increased to $300.4 million, with a gross margin of 75.2%. The loss from operations saw a reduction, and the basic and diluted net loss per share decreased to $0.66. Looking ahead, the company has provided a positive financial outlook for 2024, with projected revenue growth and an expected increase in adjusted EBITDA.